Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric Cancer
Status:
Unknown status
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of Apatinib combined with
S-1 as first-line therapy for patients with advanced gastric or gastroesophageal junction
adenocarcinoma.